The Efficacy of Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir with or without Ribavirin in Patients with Hepatitis C Undergoing Chronic Haemodialysis: A Single Center Experience
Journal Title: Viral Hepatitis Journal - Year 2019, Vol 25, Issue 3
Abstract
Objectives: Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir (PrOD) seems to be highly effective and safe in chronic haemodialysis (CHD) patients. We presented our experiences of treatment with PrOD in CHD patients. Materials and Methods: Between July 2016 and September 2018, a total of 25 CHD patients treated with PrOD were enrolled. The patients with hepatitis C virus (HCV) genotype 1a were treated with PrOD plus ribavirin (RBV) (12 or 24 weeks according to whether or not they had compensated cirrhosis), while the patients with genotype 1b were treated with PrOD alone. Liver functions, renal functions, and HCV-RNA levels were measured at baseline, 4, 12, and if applicable, 24 weeks after the initiation of treatment as well as 4 and 12 weeks after therapy. Results: Nineteen patients received PrOD, while 6 received PrOD plus RBV treatment. Two patients failed to complete the treatment. Two patients with compensated cirrhosis were treated over 24 weeks, while others received 12 weeks. In 23 patients completed 12 weeks, all were HCV-RNA negative at the end of the treatment, and had sustained virologic response (SVR) after the 12 weeks of treatment. The most common side effects were pruritus and anaemia. Conclusion: The PrOD treatment resulted in a high rate of SVR in HCV-infected CHD.
Authors and Affiliations
Nilay Danış, Hüsnü Pullukçu, Tansu Yamazhan, Galip Ersöz, Nalan Ünal, Fulya Günşar, İlker Turan, Zeki Karasu, Ulus Salih Akarca
Keywords
Related Articles
- EP ID EP676549
- DOI 10.4274/vhd.galenos.2019.2019.0028
- Views 148
- Downloads 0
Direct-acting Antiviral Therapy for Mixed Genotype Chronic Hepatitis C Infection
Objectives: Literature data concerning the outcomes of direct acting antiviral (DAA) therapy in mixed genotype hepatitis C virus (HCV) infections are very limited, and the incidence of mixed HCV infection in Turkey is un...
How Aware are We of the Immune Status of Hepatitis B and Hepatitis A in Chronic Hepatitis C Patients? A Multicenter Retrospective Study from Turkey
Objectives: Patients with chronic hepatitis C virus (HCV) infection and superinfection by hepatitis A or hepatitis B virus have higher morbidity and mortality when compared with those without HCV infection. The aim of th...
Frequency of Hepatitis Delta Virus in Hepatitis B Surfaceantigen-positive Patients
Objectives: The prevalence of hepatitis delta virus (HDV) worldwide shows geographical differences. Although there are several studies on anti-HDV seroprevalence rates in hepatitis B surface antigen (HBsAg)-positive pati...
Evaluating The Frequency of Autoantibodies in Patients with Chronic Hepatitis B
Objectives: The objective of this study is to evaluate the frequency of autoantibodies retrospectively in newly diagnosed chronic hepatitis B (CHB) patients. Materials and Methods: The study was retrospectively conducte...
Efficacy of Direct-acting Antivirals in Hemodialysis Patients with Chronic Hepatitis C: A Real-life Retrospective Study
Objectives: Hepatitis C virus (HCV) infection is common among hemodialysis (HD) patients and is associated with increased morbidity and mortality. New generation direct-acting antiviral (DAA) agents are safe and effectiv...